Key Takeaway: GE HealthCare has announced a global clinical evaluation program for its StarGuide™ GX system, a next-generation digital 4D SPECT/CT technology. This initiative involves collaboration with five renowned medical institutions across three continents, including facilities in Israel, the United States, France, and China. The program aims to enhance theranostics imaging capabilities.
Market Sentiment Analysis
POSITIVE FACTORS
Launch of a global clinical evaluation program.
Collaboration with five prestigious institutions worldwide.
Advancement in theranostics imaging technology.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+32%
120-day peak, hindsight
Typical move
2.5%
average across 3 past catalysts
Lead asset
PET MPI
Phase 3 · Coronary Artery Disease (CAD)
Full Press Release Details
CHICAGO & VIENNA--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced a global clinical evaluation program spanning three continents and five internationally recognized institutions to assess StarGuide™ GX,i its next-generation digital 4D SPECT/CT system. Participating institutions include Hadassah Medical Center in Israel; Mayo Clinic in the United States; Oncopole Claudius Regaud – Institut Universitaire du Cancer de Toulouse in France; Peking University First Hospital in China; and
Frequently Asked Questions
What is the StarGuide™ GX system?
The StarGuide™ GX is GE HealthCare's next-generation digital 4D SPECT/CT imaging system.
Which institutions are involved in the evaluation program?
The program includes Hadassah Medical Center, Mayo Clinic, Oncopole Claudius Regaud, and others.
What is the purpose of the global clinical evaluation program?
The program aims to assess and advance theranostics imaging technology.
How many continents are participating in the program?